CVR 45346951Private limited company (ApS)Engroshandel med medicinalvarer og sygeplejeartikler (464610)København KFounded 20 Jan 2025
Employees
1
Annual report 2025, average
Gross profit
23.8K
DKK, annual report 2025
Result
+18.5K
DKK, annual report 2025
Equity
58.5K
DKK, annual report 2025
Compiled by Dandex from the Central Business Register (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish company data. Connect it once and ask about Parity Pharma ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set Up DandexASPRITA LIMITED100% of capital and votes, since 29 Aug 2025
Simon James Dorrissince 20 Jan 2025
100% of capital and votessince 29 Aug 2025
Holders of 5% or more, from the owner register. CVR records shares in bands, not exact figures.
100% of capital and votes20 Jan 2025 to 29 Aug 2025
CVR records founders at incorporation. It does not record whether they are alive or still involved.
No other current company drawn.
| Metric | 2025 |
|---|---|
| Gross profit | 24 |
| Result for the year | +18 |
| Equity | 58 |
| Total assets | 445 |
| Employees (average) | 1 |
| Credit metrics (Dandex calculations) | |
| Net interest-bearing debt (NIBD, nettorentebærende gæld) | -167note 1 |
DKK thousands. Annual reports via XBRL. Employees are the annual report's average and may cover a group. 2025 covers 11 months (20 Jan to 31 Dec 2025).
Credit metrics are Dandex calculations from the filed figures, not filed values; estimates are in grey with a note. Ratios are percentages and gearing a multiple. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may. No cash flow statement filed (class A and B are exempt).
Annual report 2025
20 Jan 2025 to 31 Dec 2025, published 17 Jun 2026
Parity Pharma ApS has changed ownership. A new strategy and new needs can be expected.
Signal, a Dandex estimate. Lapses 8 Dec 2026.
Parity Pharma ApS has moved to a new address, with a potential need for new suppliers.
Signal, a Dandex estimate. Lapses 11 Jan 2027.
1 registered in CVR.
P-number 1031008111Rådhusstræde 15, 1466 København K
